Citation Report
List of articles citing

Epidemiology and burden of pancreatic cancer

DOI: 10.1016/j.lpm.2019.02.030
Presse Medicale, 2019, 48, e113-e123.

#	Paper	IF	Citations
72	Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. *Journal of Personalized Medicine*, **2019**, 9,	3.6	3
71	Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. *Cancers*, **2019**, 11,	6.6	21
70	Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer. *Acta Pharmaceutica Sinica B*, **2020**, 10, 399-413	15.5	25
69	Does biology determine survival in pancreatic cancer?. *Future Oncology*, **2020**, 16, 1-4	3.6	3
68	Transportome Malfunctions and the Hallmarks of Pancreatic Cancer. *Reviews of Physiology, Biochemistry and Pharmacology*, **2020**, 1	2.9	6
67	Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 8304-8314	5.6	5
66	Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments. *Cancers*, **2020**, 12,	6.6	6
65	[Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. *Zentralblatt Fur Chirurgie*, **2020**, 145, 354-364	2	0
64	Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis. *Dose-Response*, **2020**, 18, 1559325820942065	2.3	1
63	Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and pancreatic cancer incidence and mortality: A prospective cohort study. *Cancer Medicine*, **2020**, 9, 6843-6853	4.8	5
62	Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	0
61	FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. *Cancer Management and Research*, **2020**, 12, 10271-10278	3.6	3
60	Global, regional and national burden of pancreatic cancer, 1990 to 2017: Results from the Global Burden of Disease Study 2017. *Pancreatology*, **2020**, 20, 462-469	3.8	10
59	Islets and pancreatic ductal adenocarcinoma - An opportunity for translational research from the ꝺBench to the BedsideS *Pancreatology*, **2020**, 20, 385-390	3.8	2
58	Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. *Oncogene*, **2021**, 40, 899-908	9.2	17
57	E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBP□*Oncogene*, **2021**, 40, 262-276	9.2	7
56	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. *Acta Pharmacologica Sinica*, **2021**, 42, 1725-1741	8	6

55	Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. *Future Science OA*, **2020**, 7, FSO644	2.7	0
54	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. *Cancers*, **2021**, 13,	6.6	7
53	EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. *Endoscopy International Open*, **2021**, 9, E253-E257	3	3
52	Projected economic burden of pancreatic cancer in Sweden in 2030. *Acta Oncologica*, **2021**, 60, 866-871	3.2	2
51	Policy Analysis of Gastrointestinal Cancer Prevention in Iran: A Framework Based on a Qualitative Study. *World Medical and Health Policy*, **2021**, 13, 548-570	4.2	1
50	Pancreatic ductal adenocarcinoma survival in South Australia: time trends and impact of tumour location. *ANZ Journal of Surgery*, **2021**, 91, 921-926	1	2
49	Burden of pancreatic cancer along with attributable risk factors in Europe between 1990 and 2019, and projections until 2039. *International Journal of Cancer*, **2021**, 149, 993-1001	7.5	11
48	The Landscape of Microbial Composition and Associated Factors in Pancreatic Ductal Adenocarcinoma Using RNA-Seq Data. *Frontiers in Oncology*, **2021**, 11, 651350	5.3	2
47	Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer. *Clinical Therapeutics*, **2021**, 43, 1107-1115	3.5	1
46	Anti-proliferative, antioxidant effects of methanol extract of Calotropis procera leaf on lung cancer cells (H1299) and its ameliorative effect on expression of CD146 on blood cells. *Clinical Phytoscience*, **2021**, 7,	2.4	0
45	Global trends in pancreas cancer among Asia-Pacific population. *Journal of Gastrointestinal Oncology*, **2021**, 12, S374-S386	2.8	1
44	Pancreatic cancer: A review of epidemiology, trend, and risk factors. *World Journal of Gastroenterology*, **2021**, 27, 4298-4321	5.6	17
43	SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. *Cell Reports*, **2021**, 36, 109443	10.6	2
42	Combining Fluorescent Cell Sorting and Single B Cell Amplification to Screen the Monoclonal Antibody Gene against Human Glypican-1 in Pancreatic Cancer. *Journal of Oncology*, **2021**, 2021, 5646589	4.5	0
41	Prognostic Factors of Survival in Pancreatic Cancer Metastasis to Liver at Different Ages of Diagnosis: A SEER Population-Based Cohort Study. *Frontiers in Big Data*, **2021**, 4, 654972	2.8	1
40	Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma. *ANZ Journal of Surgery*, **2021**, 91, 2466-2474	1	1
39	Identification of N6-Methyladenosine-Associated Long Non-coding RNAs for Immunotherapeutic Response and Prognosis in Patients With Pancreatic Cancer. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 748442	5.7	1
38	Global, regional, and national survey on the burden and quality of care of pancreatic cancer: a systematic analysis for the Global Burden of Disease study 1990-2017. *Pancreatology*, **2021**, 21, 1443-1450	3.8	4

37	Divulging the Critical Role of HuR in Pancreatic Cancer as a Therapeutic Target and a Means to Overcome Chemoresistance. *Cancers*, **2021**, 13,	6.6	1
36	Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives. *Oncology Letters*, **2021**, 22, 809	2.6	0
35	Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. *Cancer Letters*, **2021**, 520, 1-11	9.9	9
34	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. *Technology in Cancer Research and Treatment*, **2021**, 20, 15330338211042139	2.7	1
33	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. *Current Cancer Drug Targets*, **2020**, 20, 887-895	2.8	4
32	Metabolic implications of pancreatic fat accumulation. *Nature Reviews Endocrinology*, **2022**, 18, 43-54	15.2	2
31	Epidemiological Characteristics of Pancreatic Cancer in China From 1990 to 2019. *Cancer Control*, **2021**, 28, 10732748211051536	2.2	0
30	Proposing a Comprehensive Prehabilitation Model for Individuals with Operable Pancreatic Cancer. *Asia-Pacific Journal of Oncology Nursing*, **2020**, 7, 255-258	2.2	1
29	A Prognostic Model of Pancreatic Cancer Based on Ferroptosis-Related Genes to Determine Its Immune Landscape and Underlying Mechanisms. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 746696	5.7	3
28	Quercetin Impact in Pancreatic Cancer: An Overview on Its Therapeutic Effects. *Oxidative Medicine and Cellular Longevity*, **2021**, 2021, 4393266	6.7	6
27	MicroRNA-374 targets JAM-2 regulates the growth and metastasis of human pancreatic cancer cells. *American Journal of Translational Research (discontinued)*, **2019**, 11, 6454-6461	3	1
26	Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.. *Nutrients*, **2022**, 14,	6.7	1
25	3,5-Bis(trifluoromethyl)phenylsulfonamides, a novel pancreatic cancer active lead. Investigation of the terminal aromatic moiety.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 61, 128591	2.9	0
24	Inflammatory potential of diet and pancreatic cancer risk in the EPIC study.. *European Journal of Nutrition*, **2022**, 1	5.2	0
23	Autophagic Schwann cells promote perineural invasion mediated by the NGF/ATG7 paracrine pathway in pancreatic cancer.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 48	12.8	1
22	Duct-to-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy.. *The Cochrane Library*, **2022**, 3, CD013462	5.2	2
21	Curcumol inhibits the growth of xenograft-tumors in mice and the biological activities of pancreatic cancer cells by regulating the miR-21-5p/SMAD7 axis.. *Cell Cycle*, **2022**, 1-18	4.7	0
20	Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis.. *Frontiers in Oncology*, **2022**, 12, 789351	5.3	1

19	Impact of biliary stenting in endoscopic ultrasound-guided tissue acquisition among patients with pancreatic cancer.. *Journal of Clinical Ultrasound*, **2022**,	1	1
18	Healthy lifestyle index and risk of pancreatic cancer in the Women's Health Initiative.. *Cancer Causes and Control*, **2022**, 1	2.8	0
17	The importance of harmonizing pancreatic EUS findings.. *Gastrointestinal Endoscopy*, **2022**,	5.2	
16	Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review.. *Expert Review of Gastroenterology and Hepatology*, **2021**, 1-7	4.2	0
15	Prophylactic abdominal drainage for pancreatic surgery.. *The Cochrane Library*, **2021**, 12, CD010583	5.2	1
14	Lifestyle, body mass index, diabetes, and the risk of pancreatic cancer in a nationwide population-based cohort study with 7.4 million Korean subjects.. *British Journal of Cancer*, **2022**,	8.7	0
13	Risk factors related to age at diagnosis of pancreatic cancer: a retrospective cohort pilot study.. *BMC Gastroenterology*, **2022**, 22, 243	3	1
12	The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer.. *Scientific Reports*, **2022**, 12, 8244	4.9	0
11	Deoxyelephantopin Suppresses Pancreatic Cancer Progression In Vitro and In Vivo by Targeting linc00511/miR-370-5p/p21 Promoter Axis. *Journal of Oncology*, **2022**, 2022, 1-19	4.5	0
10	Hepatitis B virus markers in hepatitis B surface antigen negative patients with pancreatic cancer: Two case reports. *World Journal of Hepatology*, **2022**, 14, 1512-1519	3.4	0
9	Targeting amino acid metabolism in cancer. **2022**,		0
8	Previous hepatitis B viral infection□n underestimated cause of pancreatic cancer. **2022**, 28, 4812-4822		0
7	Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. **2022**, 23, 10132		1
6	Smoking and pancreatic cancer: a sex-specific analysis in the Multiethnic Cohort study.		0
5	Recent estimates and predictions of 5-year survival rate in patients with pancreatic cancer: A model-based period analysis. 9,		0
4	Exploration of Risk Factors for Pancreatic Cancer and Development of a Clinical High-Risk Group Rating Scale. **2023**, 12, 358		0
3	Polyethyleneglycol-Betulinic Acid (PEG-BA) Polymer-Drug Conjugate Induces Apoptosis and Antioxidation in a Biological Model of Pancreatic Cancer. **2023**, 15, 448		0
2	Body mass index, C-reactive protein, and pancreatic cancer: A Mendelian randomization analysis to investigate causal pathways. 13,		0

1	Effect of Crude Extract of Clove Alcohol on the Biological Behaviour of PANC-1 Cells at 39?C. **2023**, 13, 273-281	0